Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 06:01 ET | Source: NUCLIDIUM AG

NUCLIDIUM Presents Positive Phase I/II Results for First Copper-based PET Diagnostic in Neuroendocrine Tumors at EANM Congress 2025

61Cu-TraceNETTM showed an excellent safety profile and was well tolerated with rapid blood clearance and a favorable half-life enabling broader biodistribution and extending time points for...
October 01, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM Receives Notice of Allowance for Composition-of-Matter Patent Covering FAP inhibitor-based Radiodiagnostics and Therapeutics in the United States

Basel, Switzerland / Munich, Germany, October 01, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that it...
September 16, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM to Present Clinical Data from Phase I/II Study for Copper-based PET-Diagnostic in Neuroendocrine Tumors at EANM 2025

Basel, Switzerland / Munich, Germany, September 16, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that...
July 10, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B Financing to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform

Proceeds will fund further clinical development of the company’s true theranostic pipeline and expansion of the global production and manufacturing network for copper-based...
June 24, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM Presents Positive Phase 1 Results of its Novel PET Imaging Agent 61Cu-NuriPro™ at SNMMI 2025 Annual Meeting

61Cu-NuriPro™ detected more lesions up to 4 hours post-administration in 50% of patients, not visualized by 18F-piflufolastat PET1,2 Dosimetry data highlight favorable tumor-to-background ratio with...